OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including statements with respect to revenues, earnings, technology, new products, product performance, markets, clinical development, regulatory filings and approvals, and business plans. Factors affecting these statements include, but are not limited to, the ability to develop new technology, technology changes, ability to fund research and development, required regulatory approvals, product performance and market acceptance of products. Please see the Company s SEC filings, including its registration statements, and the Company s most recent Form 10-K and Form 10-Q, for a more detailed description of specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. The Company undertakes no duty to update these statements. 2
Investment Summary Industry leader in rapid point-of-care infectious disease testing and DNA/RNA sample collection, stabilization and preparation products Three Significant Growth Opportunities: Approved products address large global markets - current penetration rates low but momentum is building Well positioned with market leading rapid tests: HCV test OTC HIV test Molecular diagnostic sample collection Strong balance sheet, no debt 3
OraQuick HCV Addressing a Significant Unmet Need 170 million people infected globally, 4-5 million people infected in U.S. -- The majority of HCV infection remains undiagnosed Newly approved drugs, and those in the pipeline, are expected to drive demand for increased diagnoses and increase the number of patients initiating therapy Availability of a rapid, non-instrumented POC test will increase opportunities for diagnosis through increased testing outside of laboratory settings 4
OraQuick HCV Rapid HCV Antibody Test The first FDA-approved, CLIA-waived rapid HCV test HHS issued Hepatitis Action Plan in May 2011, updated in 2014 CDC issued new screening guidelines to test all baby- boomers (born 1945 1965), 80 million Americans Testing all baby-boomers is estimated to be a $1B revenue opportunity in the U.S. for HCV diagnostic testing USPSTF and CMS recommend reimbursement for baby-boomer screening 5
OraQuick ADVANCE Rapid HIV-1/2 Antibody Test The only FDA-approved, CLIA-waived oral fluid rapid HIV- 1/2 test. Highly accurate test results in 20 minutes Current U.S. market opportunity $200M Used by diverse customers, e.g., hospitals, public health facilities, physician offices, jails, medical clinics Over 30 million tests sold since FDA approval Marketed in public health and hospital channels by our direct sales force in the U.S. 6
OraQuick In-Home HIV Test FDA approved at-home HIV test for sale directly to consumers in the over-the-counter (OTC) market Distribution Strategy- enable consumer to purchase on line and in leading healthcare retailers www.oraquick.com Consumer Support Network (24/7 live call center and website) to provide information and linkage to care 7
OraQuick In-Home HIV Test Path Forward Implementing new strategy that should improve returns on invested capital Continue to collaborate with retail community to expand access to product Leverage trade partners to drive consumption Continue to support testing efforts of advocacy and public health groups Actively pursue regulatory approval in international markets 8
DNA Genotek - Product Overview DNA Genotek s powerful platforms have been leveraged to create multiple product line extensions Human Genetics Infectious Disease Genetics Animal & Livestock Genetics Oragene - Dx collection device is the first and only saliva DNA collection and stabilization device to receive 510(k) clearance. 9
DNA Genotek - Oral Sample Collection Anytime, anywhere sample collection Easy, reliable and non-invasive Ambient temperature stability Captures high quality DNA and RNA Scalable 10
2013 Sales Mix Dist 4% ROW 6% Academic 33% EU 19% Commercial 62% North America 75% Commercial / Academic mix ~ 62%/37% Commercial revenues are predominately in North America Tripling of capacity on-line 2Q14 11
Cumulative Totals Oragene Helping Drive Results Improving donor registry growth = increasing donor HLA matches to help save lives 25000 20000 New donor Recruitment Cumulative Totals 15000 10000 2009 2007 2008 2010 5000 0 1 2 3 4 5 6 7 8 9 10111213141516171819202122232425262728293031323334353637383940414243444546474849505152 Week 12
DNA Genotek R&D Pipeline Stabilization and preservation reagent systems for blood fraction storage at ambient temperatures Stabilization and lysing reagents to improve recoverability of Tuberculosis DNA for Molecular Diagnostic testing Microbiome stabilization reagents and transport devices 13
Summary Approved products address substantial opportunities in HCV, HIV and molecular diagnostics Diversified revenue stream Strong capital structure to support growth 14